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prepared to coordinate scientific
efforts. To improve preparedness
for future pandemics, we have ini-
tiated a network of nine European-
funded Cooperation in Science and
Technology (COST) Actions that
can help facilitate inter-, multi-, and
The world has witnessed several pan-
demics in the last 100 years: the 1918
pandemic (H1N1 virus), the 1957–1958
pandemic (H2N2 virus), the 1968 pan-
demic (H3N2 virus), and the 2009 H1N1
pandemic (H1N1pdm09 virus). Other
emergent diseases have caused serious
epidemics, such as SARS in 2003, Middle
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Despite the international guide-
lines on the containment of the
coronavirus disease 2019 (COVID-19)
pandemic, the European scientific
community was not sufficiently
trans-disciplinary communication
and collaboration.
COVID-19 emerged at the end of 2019
as a novel zoonotic disease caused by
the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2). The World
Health Organization (WHO) declared this
disease a pandemic on the March 11
2020 [1]. As of the beginning of October
2020, this emergent new virus has infected
more than 34 million people and caused
more than 1 million deaths worldwide
(https://coronavirus.jhu.edu/map.html).
Other infectious diseases are also responsi-
ble for many deaths. For example, seasonal
flu causes 290 000 to 650 000 respiratory
deaths every year [https://www.who.int/
news-room/fact-sheets/detail/influenza-
(seasonal)]. This has triggered little reaction
other than recommending vaccination,
indicating that the supposedly common
thread that should link every action, from
prevention to therapy, still has several
gaps, despite our thorough knowledge
of this disease. Established international
guidelines have been published for











no country has been sufficiently prepared
to tackle the COVID-19 pandemic, despite
this support.
East respiratory syndrome (MERS) in
2012, and Ebola in 2014 (https://www.
cdc.gov/flu/pandemic-resources/basics/
past-pandemics.html). Sufficient time has
passed and both science and technology
have significantly evolved. So why were
we not better prepared? Why did we not
have a better coordination of scientific
efforts to control, prevent, and treat
COVID-19?
The first peak of the COVID-19 pandemic
has seen unprecedented efforts by the sci-
entific community. However, the international
scientific community needs to be better pre-
pared for the ongoing second wave of
COVID-19 and for future pandemics.
In our opinion, four pieces of evidence
showing the lack of coordinated action
among scientists have emerged during
the COVID-19 pandemic.
First, the whole world in general, and
Europe in particular, has suffered from a se-
vere lack of accessible and comprehensive
multinational platforms to facilitate inter-
disciplinary discussion and collaboration.
Although national-level initiatives have
provided a good starting point for collab-
orative platforms in several countries, as
far as we know, these national platforms
did not join international interdisciplinary
networks. In our opinion, the lack of inter-
national and interdisciplinary networks has
slowed down Europe’s capacity to react
quickly and control the disease effectively.
Second, reliable scientific information has
been scattered. With the pandemic under-
way, the amount of scientific information
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has been overwhelming and sometimes
widely dispersed among articles that have
reported conflicting data.
Third, there has been a lack of coordina-
tion between research laboratories with
complementary expertise and resources.
Fourth, in most cases, communication
between scientists, governments, and
national and international organizations
[such as the WHO, National Institutes of
Health (NIH), Centers for Disease Control
and Prevention (CDC), and European
Centre for Disease Prevention and Control
(ECDC)], has been guarded rather than
being open, contributing to the lack of
timeliness in public-health response. This
guardedness was not due to negligence,
but was simply because the limited infor-
mation on COVID-19, that single research
institutions and hospitals started to collect
in Europe, has not been effectively shared.
Neither the ongoing nor future pandemics
will be solved by a solution provided by a
single research discipline. Multilayered
solutions will be required, which means
that scientists from different areas of re-
search must join forces, communicate bet-
ter across and within their own disciplines,
and share resources (e.g., samples
from biological banks, data repositories,
instrumentation, and expertise).
Organizing an inclusive platform to allow
inter- and trans-disciplinary networking
on emerging infectious diseases is an
urgent need in Europe. Ideally, this platform
could contribute towards international
collaboration between scientists. It could
work closely with pre-existing national plat-
forms, become an active partner for future
trans-national initiatives, or liaise with inter-
national organizations and decisionmakers.
By accelerating the exchange of scientific
information and expertise and by proposing
international plans to act immediately at
diagnostic and research level, the platform
would produce reciprocal benefits for
scientists and stakeholders against future
waves of COVID-19.
European Cooperation in Science and
Technology (COST) is an organization
that promotes bottom-up ideas across
multiple disciplines and creates networks
(i.e., COST Actions, funded by EU research
and innovation framework programs).
COST Actions include scientists, principally
from European countries, working on spe-
cific topics in disciplines such as social
sciences and humanities, physical sciences
and engineering, or life sciences. These
networks promote the rapid exchange
of knowledge, expertise, and research,
by funding meetings, training schools,
and short-term tenures at the institutions
of members involved in COST Actions.
Unlike other EU-funded consortia that
are fixed from the moment they are
established, COST Actions are flexible,
as they accept new members, including
academic and public institutions, private
companies, non-governmental organiza-
tions, and European and international
organizations, at any point in time after in-
ception.
Given this flexibility of COST Actions, we
believe that the previously mentioned col-
laborative scientific anti-pandemic ap-
proaches can be coordinated in Europe
by a novel Trans-COST Actions initiative.
With this aim, in April 2020, we initiated
an informal Trans-COST Action network
on COVID-19, gathering scientists from
nine COST Actions with different exper-
tise (Figure 1) (https://www.cost.eu/
news/cost-actions-unite-efforts-in-the-
fight-against-covid-19/).
In the last 3 months, 64 Actions have
collaborated, with the aim of initiating an-
other mega-network supported by COST
Association, including disciplines from 11
core scientific fields (https://www.cost.
eu/wp-content/uploads/2020/06/COST_
CovidBooklet_V10.pdf). Other European
networks have also been established
during the course of the pandemic: the
Dariah-EU, to assess the societal and




of-covid-19/), the European Clinical
Research Infrastructure Network (https://
ecrin.org/), theConfederation of Laboratories
for Artificial Intelligence Research in Europe
(https://claire-ai.org/), The Institute Pasteur
International Network Collective Effort,
involving member institutes from Europe,
Asia, and Africa (https://www.pasteur.fr/
en/covid-19-pandemic-institut-pasteur-
international-network-collective-effort),
the NetworkMedicine Alliance and Institute
(https://www.network-medicine.org/), and
the EU-CardioRNA Task Force, which
launched a ‘call to action for the cardiovas-
cular side of COVID-19’ [2]. Moreover,
other initiatives around the world have
emerged, such as the ‘Covid-19 action
initiative’ promoted by the American
Lung Association (https://www.lung.org/
research/about-our-research/covid19-
action-initiative) and the ‘Global Health
Platform’ (https://pti-saludglobal-covid19.
corp.csic.es/en/). Even though the Trans-
COST Actions network mostly fosters
internal collaborations, we will interact with
these other emerging networks.
At present, the Trans-COST Action net-
work (Table 1) provides an unprecedented
platform to promote interaction between
scientists with complementary expertise
and skills, as it gathers critical mass
from diverse disciplines, including virology,
epidemiology, sociology, clinical disciplines
involved in the treatment of COVID-19
(e.g., intensive care, pneumology, cardiol-
ogy, neurology, nephrology), bioinformatics,
medicinal chemistry, pharmacology, and
cell biology. This cross-disciplinarity speeds
up scientific collaborations and achieve-
ments. For instance, the know-how of a vi-
rologist on SARS-CoV-2 may help cell
biologists to select the best in vitro tools to
understand the pathogenesis of COVID-
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Figure 1. Trans-Cooperation in Science and Technology (COST) Action Network at a Glance. Representation of the Trans-COST Action network. Colored
circles represent the nine participating COST Actions; the contents of the circles indicate the number of experts participating in each Action and the number of
countries involved. Other non-EU countries that are members of those Actions have been also listed. The Trans-COST Action network has been organized into six
work groups or research lines: epidemiology, prevention, viral pathogenesis, diagnosis and prognosis, vaccines and immunological studies, and new drug
development for the treatment of coronavirus disease 2019 (COVID-19).
19, medicinal chemists and pharmacolo-
gists to design putative antiviral agents,
and clinicians to treat patients infected with
SARS-CoV-2.
Even though the coordination of such a
large network will be difficult, as the
main organizers of this currently informal
platform, we will work towards obtaining
formal recognition by COST, including
the necessary funding for the improved
coordination of scientific effort when facing
pandemic situations. In fact, although
COST networks are always very large,
COST has had many success stories that
prove its effective approach in managing
and coordinating networks. One example
is the AMiCI ePlatform (https://sub.samk.
fi/projects/amici-eplatform/), which is a
part of the COST network that was born
from a previous COST Action and is
supported by Horizon 2020 (the biggest
EU-funded research and innovation pro-
gram for the period 2014–2020). The
AMiCI ePlatform aims to define a ‘test
bed’ tool for antimicrobial coating solu-
tions in health care.
The Trans-COST Action network has
been discussing the key steps that need
to be undertaken, from both scientific and
public-health perspectives, while tackling
COVID-19, since these two areas are
interconnected during a pandemic. For
example, the screening of European
Medicines Agency- and FDA-approved
drugs for cardiovascular or inflammatory
diseases using virtual screening, followed
by biological validation assays, could be
effectively translated into methods to ra-
tionally select drugs for testing in infected
patients. Another example is the ongoing
research into improving the chemical
properties of antimicrobial coatings and dis-
infectants, which could be readily exploited
to recommend specific cleaning guidelines
for public places where the risk of transmis-
sion is higher.
As soon as it was created, the Trans-
COST Action COVID-19 network set
goals, research lines, and means of coop-
eration via remote calls. To enable collabo-
rations, the platform immediately facilitated
rapid contact with suitable and comple-
mentary experts via a simple survey to
identify each member’s expertise and,
also, the expertise that they require. The
sharing of basic research expertise (e.g.,
cellular models to simulate SARS-CoV-2
adhesion and replication, techniques to
monitor viral proliferation and cell damage,
tools for drug synthesis and drug-target
prediction, platforms for drug screening,
computational modeling, and artificial
intelligence-based algorithms) and trans-
lational information (e.g., clinical data-
bases reporting information of diagnosis
and follow-up of COVID-19 patients, bio-
logical samples such as blood and ex-
haled breath condensate) has favored
the complementation of skills and the de-
velopment of collaborations.
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In addition to published studies [3–5], the
first successes were the development of
the COVEX software (https://exbio.wzw.
tum.de/covex/) to study the SARS-CoV-2
and SARS-CoV-1/host interactome [6] and
the generation of the Drug Repositioning
And Cooperation Database (DRACD;
https://dracdb.mohrkeg.co.at/dracdb).
DRACD will allow the upload of informa-
tion on FDA-approved drugs or novel
substances that our medicinal chemists
may have synthesized. Following upload,
DRACD queries databases on known
substance–target interactions. Finally,
contact information is stored to allow
rapid contact with users that own a par-
ticular substance, thus facilitating collab-
orations between groups that work on
the same molecule. These tools are all
freely accessible and integrated with the
latest tools for drug repurposing (https://
arvix.org/abs/2004.07229). An additional
initial success in terms of public health ac-
tivities was the involvement of one of the
network’s Actions in the preparation of
the guidelines on ‘Clinical, biochemical,
immunogenetic paradigms of COVID-19
infection and their correlation with socio-
demographic, etiological, pathogenetic,
diagnostic, therapeutically andprognostically
relevant factors’, which is part of the Latvian
‘COVID-19 MITIGATION program. This in-
volvement will be supported by the net-
work’s wide range of expertise.
We intend to empower COVID-19 research
by avoiding its confinement to a restricted
number of high-security laboratories that
can work with the pathogen. The existence
of an inclusive and multidisciplinary group
of experts will help, in a step-by-step
manner, our understanding of infection
mechanisms and expedite drug screening
and repurposing and the development of
vaccination strategies. This is necessary
to speed up the screening of treatment op-
tions and of exploratory research lines that
are set up in laboratories that work with
surrogate models of SARS-CoV-2. After
such screening, only the most promising
research lines will be subsequently vali-
dated by the few available high-security
virology laboratories working with the
real pathogen.
Even though the network was initiated very
recently, the platform has already gathered
2863 researchers from 49 countries. To
become operational, we have organized
our network into six working groups
(Figure 1) that are gathering critical mass
to move in four directions. First, we are
drafting a roadmap for each of the afore-
mentioned disciplines (Table 1) to facilitate
faster responses to emergencies. Second,
we are creating a network of laboratories
that are equipped to quickly work on
the diagnosis, treatment, and prevention
of SARS-CoV-2 infection. Third, we are
building a core set of trans-disciplinary re-
search tools that would be available to the
scientific community to aid research into
COVID-19 and future pandemics. Finally,
we are exploiting the tools and resources
present in the network, to gather available
clinical and epidemiological data, and to
work on new pharmacological strategies
to treat COVID-19 and develop new anti-
microbial solutions to prevent infection.
Concluding Remarks
Coordinating scientific effort in Europe, and
beyond, and integrating our activities with
other similar networks in non-European
countries will contribute to the development
of faster andmore effective ways to prevent,
control, and treat pandemics, with obvious
health and social benefits. What we learn
from the ongoing COVID-19 pandemic will
help us to establish strategies to combat
future pandemics. In this sense, the current
pandemic may become a paradigmatic
‘opportunity’ for future pandemic mitigation
strategies.
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